Steffie-Ann Dujon, MD
Internal Medicine · Norman, OKNPI 1922637131
Payments from drug & device makers
Across 122 payments — averaging $21.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$363
- GSK$298
- Amgen$280
- Pfizer$271
- AbbVie$181
- Shield Therapeutics Inc$138
- plus $1K from 22 others
What the payments were for
- Food & beverage$2,576100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 14 | $363 |
| GSK | 12 | $298 |
| Amgen | 12 | $280 |
| Pfizer | 16 | $271 |
| AbbVie | 9 | $181 |
| Shield Therapeutics Inc | 3 | $138 |
| Lilly USA, LLC | 8 | $136 |
| Novo Nordisk | 6 | $107 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $98 |
| Baxter Healthcare | 3 | $80 |
| Idorsia Pharmaceuticals US Inc | 5 | $79 |
| Phathom Pharmaceuticals, Inc. | 4 | $58 |
| Astellas Pharma US Inc | 2 | $49 |
| Teva Pharmaceuticals USA, Inc. | 2 | $46 |
| Sumitomo Pharma America, Inc. | 2 | $39 |
| Bayer | 2 | $36 |
| Merck | 2 | $36 |
| Cequr Corporation | 1 | $35 |
| Sanofi-aventis U.S. LLC | 2 | $34 |
| Xeris Pharmaceuticals, Inc. | 2 | $32 |
| Exact Sciences | 2 | $31 |
| Boehringer Ingelheim | 2 | $28 |
| Eisai Inc. | 1 | $24 |
| IBSA Pharma Inc. | 1 | $22 |
| Medtronic | 1 | $22 |
| Dexcom, Inc. | 1 | $21 |
| Johnson & Johnson | 1 | $16 |
| Axsome Therapeutics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,576 in reported general payments places this provider in the 80th percentile of 840 internal medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 72 | $93,885 |
| JardianceEmpagliflozin | 42 | $63,812 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $53,490 |
| EliquisApixaban | 31 | $34,824 |
| MounjaroTirzepatide | 30 | $33,770 |
| FarxigaDapagliflozin Propanediol | 18 | $21,963 |
| RybelsusSemaglutide | 12 | $15,576 |
| MyrbetriqMirabegron | 12 | $12,050 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 14 | $9,563 |
| BelsomraSuvorexant | 13 | $6,285 |
| Atorvastatin Calcium | 228 | $6,145 |
| Potassium Chloride | 118 | $3,568 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $3,500 |
| Gabapentin | 171 | $3,366 |
| Levothyroxine Sodium | 228 | $2,829 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $107 | $109,46184 claims |
| Boehringer IngelheimJardiance | $28 | $63,81242 claims |
| GSKTrelegy Ellipta | $298 | $53,49036 claims |
| PfizerEliquis | $271 | $34,82431 claims |
| Lilly USA, LLCMounjaro | $136 | $33,77030 claims |
| AstraZenecaFarxiga, Symbicort | $363 | $25,46233 claims |
| Astellas Pharma US IncMyrbetriq | $49 | $12,05012 claims |
| MerckBelsomra | $36 | $6,28513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 840 internal medicine providers in Oklahoma.
Other internal medicine in Norman
- Elise WiesnerNorman$584K
- Mudassir NawazNorman$10K
- Al-Ola AbdallahTulsa$10.1M
- Melita TateTulsa$9.1M
- Sagila GeorgeOklahoma City$1.8M
- Ryan MorganOklahoma City$775K
- Renae MayerTulsa$766K
- George FreemanIdabel$742K
- Steve EgwuonwuLawton$464K
- Mousumi SomTulsa$391K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.